MTT assay was performed with different concentrations of TRAIL and TNFα treatment alone and in combination with BV6 (1 μM) to investigate its antitumor activity and cell viability on the breast cancer cells MCF7 and MDA-MB-231. The gene discussed is TNFSF10; the disease is breast carcinoma.